Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:41:54.877Z.
Consensus retrieved: 2026-10-06T12:54:35.831Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:41:54.877Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 97f82c903e8e6ec217280dce7f3fe4a68629f44b5a27270464b7740b55d93be6
Forward PE Ratio (N/A) = Dated Quote Price ($4.38) / Consensus Forward EPS ($-1.04)
FORWARD PE RATIO
N/A
Opus Genetics, Inc.
Market Cap
$361.64M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Opus Genetics, Inc. (IRD) | $361.64M | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 36.53 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 22.57 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | N/A |
| Embecta Corp. (EMBC)vs › | $353.00M | 3.38 |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.50M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.38, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.04 | $-1.30 – $-0.29 | 13 | n/m |
| 2027-12-31 | $-0.70 | $-1.24 – $-0.40 | 12 | n/m |
| 2028-12-31 | $-0.28 | $-0.82 – $1.03 | 12 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
